

eversense^{E3}
Continuous Glucose Monitoring System

Your Patients Deserve to Live Life Uninterrupted

Eversense E3 CGM System is the only CGM with 6 months of continuous glucose readings designed to reduce interruptions that stand in the way of optimal care.



The CGM for REAL LIFE




Eversense E3 is Designed to Overcome the Limitations of Short-Term CGM Systems


#1 CGM in Survivability & Longevity¹⁻³

95% of Eversense E3 sensors survive the full 6 months² – which means fewer interruptions in CGM care.

Sensor Survivability¹⁻³




Expected Sensor Life¹⁻³



Most Accurate in Low Glucose Ranges¹⁻³

Eversense E3 has unparalleled accuracy **when it matters the most.**¹⁻³


Best Accuracy in the Severe Hypoglycemic Range¹⁻³



1. Senseonics. (2023) Eversense E3 Continuous Glucose Monitoring System User Guide. LBL-6002-01-001_Rev C
2. Dexcom. (2023) G7 User Guide. AW00078-10 Rev 002 MT-00078-10
3. Abbott. (2022) FreeStyle Libre 3 Flash Glucose Monitoring System User Manual. ART43911-001 Rev. B 06/22


Delivers Accurate Readings with Only 1 Day One Across 6 Months¹⁻³

Across 180 days of transcutaneous sensor wear, there are **18 sensor sessions with associated variability for each.**⁴




Most Dependable Detection Alerts

On-body alerts discreetly notify of predictive high or low.



Low glucose events
detected correctly
(70 mg/dL)¹



High glucose events
detected correctly
(180 mg/dL)¹

Almost No Skin Reactions from Adhesive (less than 1%)¹

Easy-on, easy-off smart transmitter gives your patients the freedom to detach **without wasting a sensor***

* There is no glucose data generated when the transmitter is removed.

1. Senseonics. (2023) Eversense E3 Continuous Glucose Monitoring System User Guide. LBL-6002-01-001_Rev C

2. Dexcom. (2023) G7 User Guide. AW00078-10 Rev 002 MT-00078-10

3. Abbott. (2022) FreeStyle Libre 3 Flash Glucose Monitoring System User Manual. ART43911-001 Rev. B 06/22

4. Garg SK, Kipnes M, Castorino K, Bailey TS, Akturk HK, Welsh JB, Christiansen MP, Balo AK, Brown SA, Reid JL, Beck SE. Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes. Diabetes Technol Ther. 2022 Jun;24(6):373-380.

Eversense E3 is Designed for Those Seeking CGM Longevity, Reliability, and Flexibility

An optimal choice for adults with T1 or T2 diabetes on insulin.

Unable to Monitor Mobile Alerts

Skin Sensitivity

Frequent Hypoglycemic Events / Hypo Unawareness

Active Lifestyle

Frequent Compression Lows

Desire Discretion & Flexibility

Help Your Patients TODAY
Live A Life Uninterrupted!

Your Eversense Contact

Name _____

Email _____

Phone _____

eversense^{E3}
Continuous Glucose Monitoring System



Distributed by Ascensia Diabetes Care
5 Wood Hollow Road
Parsippany, NJ 07054
844-SENSE4U (736-7348)
ascensiadabetes.com/eversense

Manufactured by Senseonics, Inc.
20451 Seneca Meadows Parkway
Germantown, MD 20876-7005 USA

The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.

For safety information, see <https://www.ascensiadabetes.com/eversense/safety-info/>

Eversense, Eversense E3 Continuous Glucose Monitoring and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia and the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. Android is a trademark of Google LLC. Apple Watch is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied. PP-SENS-E3-GBL-0050 (v1.06/24)

© 2024 Senseonics, Inc. All rights reserved.
© 2024 Ascensia Diabetes Care Holdings AG. All rights reserved.